UnknownPhase 4

Efficacy and Mortality of a Loading Dose of Colistin in Critical Ill Patients

Chile200 participantsStarted 2014-04

Plain-language summary

The study hypothesis is that the loading dose of intravenous colistin (6 million of international units) is associated with greater clinical and microbiological efficacy, and reduced mortality of critically ill patients infected by multidrug resistant Gram- negative bacilli, compared to a scheme without loading dose.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * patient hospitalized in critical care units * patient infected by multi drug resistant Gram negative bacteria susceptibly only to colistin * source of infection: blood, respiratory, intra abdominal or urinary Exclusion Criteria: * pregnant or breastfeeding patients * patient with a history of hypersensitivity to colistin

What they're measuring

Percentage of patients with clinical response to treatment

Timeframe: up to 1 week

percentage of patients with microbiological response

Timeframe: up to 1 week

mortality

Timeframe: during their stay in the intensive care unit

Trial details

NCT IDNCT02117986

SponsorHospital Barros Luco Trudeau

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2018-12

Contact for this trial

Loreto Rojas, MD

56-9-68479281 rojasloreto@gmail.com

View on ClinicalTrials.gov More Gram Negative Bacterial Infections trials